MEDIPOST met all primary and secondary efficacy endpoints in the Japan Phase III clinical trial of CARTISTEM knee osteoarthritis treatment, demonstrating clinical improvements in pain and function as well as cartilage regeneration. Based on the results, MEDIPOST is expected to accelerate preparations for its biologics license application filing in Japan later this year.
The trial was a randomized, controlled study conducted at 13 sites in Japan, enrolling 130 participants. Subjects were randomized into the CARTISTEM treatment group, comprising 59 patients, and the hyaluronic acid (HA) control group, comprising 61 patients. Efficacy and safety were evaluated over a 52-week follow-up period.
CARTISTEM maintained an excellent safety profile throughout the trial. All reported serious adverse events were assessed as having no causal relationship to CARTISTEM.
At the top of 2026, the company closed on $140 million in funding to accelerate a U.S. Phase III clinical trial of its investigational mesenchymal stem cell therapy in the treatment of symptomatic cartilage defects in patients with knee osteoarthritis.
MEDIPOST met all primary and secondary efficacy endpoints in the Japan Phase III clinical trial of CARTISTEM knee osteoarthritis treatment, demonstrating clinical improvements in pain and function as well as cartilage regeneration. Based on the results, MEDIPOST is expected to accelerate preparations for its biologics license application filing...
MEDIPOST met all primary and secondary efficacy endpoints in the Japan Phase III clinical trial of CARTISTEM knee osteoarthritis treatment, demonstrating clinical improvements in pain and function as well as cartilage regeneration. Based on the results, MEDIPOST is expected to accelerate preparations for its biologics license application filing in Japan later this year.
The trial was a randomized, controlled study conducted at 13 sites in Japan, enrolling 130 participants. Subjects were randomized into the CARTISTEM treatment group, comprising 59 patients, and the hyaluronic acid (HA) control group, comprising 61 patients. Efficacy and safety were evaluated over a 52-week follow-up period.
CARTISTEM maintained an excellent safety profile throughout the trial. All reported serious adverse events were assessed as having no causal relationship to CARTISTEM.
At the top of 2026, the company closed on $140 million in funding to accelerate a U.S. Phase III clinical trial of its investigational mesenchymal stem cell therapy in the treatment of symptomatic cartilage defects in patients with knee osteoarthritis.
Copy to clipboard 
